Cargando…

Retrospective analysis of the diagnostic yield of newborn drug testing

BACKGROUND: The objective of this study was to identify high-yield screening risk factors for detecting maternal non-medical drug use during pregnancy. METHODS: A four year retrospective analysis was conducted at an academic medical center. Detailed chart review of both the newborn and mother’s medi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wood, Kelly E, Sinclair, Lori L, Rysgaard, Carolyn D, Strathmann, Frederick G, McMillin, Gwendolyn A, Krasowski, Matthew D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124162/
https://www.ncbi.nlm.nih.gov/pubmed/25073780
http://dx.doi.org/10.1186/1471-2393-14-250
_version_ 1782329593177309184
author Wood, Kelly E
Sinclair, Lori L
Rysgaard, Carolyn D
Strathmann, Frederick G
McMillin, Gwendolyn A
Krasowski, Matthew D
author_facet Wood, Kelly E
Sinclair, Lori L
Rysgaard, Carolyn D
Strathmann, Frederick G
McMillin, Gwendolyn A
Krasowski, Matthew D
author_sort Wood, Kelly E
collection PubMed
description BACKGROUND: The objective of this study was to identify high-yield screening risk factors for detecting maternal non-medical drug use during pregnancy. METHODS: A four year retrospective analysis was conducted at an academic medical center. Detailed chart review of both the newborn and mother’s medical record was performed on all cases for which one or more drug(s) or metabolite(s) were identified and confirmed in meconium or urine. RESULTS: 229 (9.2%) of 2,497 meconium samples out of 7,749 live births confirmed positive for one or more non-medical drugs. History of maternal non-medical drug and/or tobacco use in pregnancy was present in 90.8% of non-medical drug use cases. Addition of social risk factors and inadequate prenatal care increased the yield to 96.9%. CONCLUSIONS: Use of focused screening criteria based on specific maternal and social risk factors may detect many prenatal non-medical drug exposures. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2393-14-250) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4124162
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41241622014-08-08 Retrospective analysis of the diagnostic yield of newborn drug testing Wood, Kelly E Sinclair, Lori L Rysgaard, Carolyn D Strathmann, Frederick G McMillin, Gwendolyn A Krasowski, Matthew D BMC Pregnancy Childbirth Research Article BACKGROUND: The objective of this study was to identify high-yield screening risk factors for detecting maternal non-medical drug use during pregnancy. METHODS: A four year retrospective analysis was conducted at an academic medical center. Detailed chart review of both the newborn and mother’s medical record was performed on all cases for which one or more drug(s) or metabolite(s) were identified and confirmed in meconium or urine. RESULTS: 229 (9.2%) of 2,497 meconium samples out of 7,749 live births confirmed positive for one or more non-medical drugs. History of maternal non-medical drug and/or tobacco use in pregnancy was present in 90.8% of non-medical drug use cases. Addition of social risk factors and inadequate prenatal care increased the yield to 96.9%. CONCLUSIONS: Use of focused screening criteria based on specific maternal and social risk factors may detect many prenatal non-medical drug exposures. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2393-14-250) contains supplementary material, which is available to authorized users. BioMed Central 2014-07-29 /pmc/articles/PMC4124162/ /pubmed/25073780 http://dx.doi.org/10.1186/1471-2393-14-250 Text en © Wood et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wood, Kelly E
Sinclair, Lori L
Rysgaard, Carolyn D
Strathmann, Frederick G
McMillin, Gwendolyn A
Krasowski, Matthew D
Retrospective analysis of the diagnostic yield of newborn drug testing
title Retrospective analysis of the diagnostic yield of newborn drug testing
title_full Retrospective analysis of the diagnostic yield of newborn drug testing
title_fullStr Retrospective analysis of the diagnostic yield of newborn drug testing
title_full_unstemmed Retrospective analysis of the diagnostic yield of newborn drug testing
title_short Retrospective analysis of the diagnostic yield of newborn drug testing
title_sort retrospective analysis of the diagnostic yield of newborn drug testing
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124162/
https://www.ncbi.nlm.nih.gov/pubmed/25073780
http://dx.doi.org/10.1186/1471-2393-14-250
work_keys_str_mv AT woodkellye retrospectiveanalysisofthediagnosticyieldofnewborndrugtesting
AT sinclairloril retrospectiveanalysisofthediagnosticyieldofnewborndrugtesting
AT rysgaardcarolynd retrospectiveanalysisofthediagnosticyieldofnewborndrugtesting
AT strathmannfrederickg retrospectiveanalysisofthediagnosticyieldofnewborndrugtesting
AT mcmillingwendolyna retrospectiveanalysisofthediagnosticyieldofnewborndrugtesting
AT krasowskimatthewd retrospectiveanalysisofthediagnosticyieldofnewborndrugtesting